Loredana Arrico

Loredana Arrico

Auto-generated profile, based on publicly available information

Loredana Arrico

Institute of Ophthalmology, La Sapienza University, Rome

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
EPelena pacella
elena pacella
Lorenzo LoffredoLorenzo Loffredo
Lorenzo Loffredo
MMMariaelena Malvasi
Mariaelena Malvasi
EBEdoardo Trovato Battagliola
Edoardo Trovato Battagliola
Daniela MessineoDaniela Messineo
Daniela Messineo
LALoredana Arrico
Loredana Arrico
Purpose: Dexamethasone and other corticosteroids are administered intravitreally to treat a variety of retinal diseases. As a side effect, they can alter intraocular pressure (IOP). The purpose of this study is to describe the incidence, severity, and management of ocular hypertension following the administration of multiple intravitreal injections of dexamethasone implants. Materials and Methods: A total of 78 eyes of 78 subjects (males 62%; females 38%; mean age 67 ± 13 years SD) received a total of 152 intravitreal injections of 0.7 mg dexamethasone implants over 4 years. Indications included retinal vein occlusion (87%), diabetic macular edema (9%), wet-type age-related macular degeneration (4%). Ocular hypertension was defined as intraocular pressure above 23 mmHg or any pressure increase of 10 mmHg or more from baseline values. IOP was measured by applanation tonometry before the injection (T0), as well as one week (T1), one month (T2), and three months (T3) afterwards. Results: Five percent (4/78) of subjects developed ocular hypertension after the 1st injection. On the second and third rounds, additional 7.2% (3/42) and 4.2% (1/24) of subjects developed the same side effect. Among the 8 subjects who received a fourth injection, none was found with OHT. Pressure elevations were detected at T2 and T3. In all patients, topical medical therapy was sufficient to lower the IOP below threshold. Mean pressure variations following the first injection as compared to previous recorded values were +0.97 mmHg (T1), +0.92 mmHg (T2), and − 0.41 mmHg (T3) (p < 0.05). Mean pressure variations following the second injection were +0.54 mmHg (T1), +0.23 mmHg (T2) and − 0.66 mmHg (T3) (p < 0.05). Conclusion: Ocular hypertension is a recognized side effect of intravitreal dexamethasone. Some patients develop it right after the first injection, while others develop it subsequently, on the 2nd or 3rd round. This side effect becomes most apparent 30– 90 days following the implantation procedure and responds well to topical pressure-lowering medications.

11 June 2015 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
LAL. Arrico
L. Arrico
AAA. Abbouda
A. Abbouda
IAIrene Abicca
Irene Abicca
RMR. Malagola
R. Malagola
Ocular complications associated with cutaneous lupus erythematosus (CLE) are less studied compared with those ones associated with systemic lupus erythematosus (SLE). The main ocular sites involved in patients affected by discoid lupus erythematosus (DLE) are eyelids followed by orbit and periorbit, the least being cornea. The most common complications are blepharitis usually affecting the lower lid and associated with some type of lid lesion such as plaque or erythematosus patches and madarosis. Few cases with LE profundus (LEP) and ocular complications are reported, but they are associated with orbital inflammatory syndrome and severe complications. The main treatment prescribed is hydroxychloroquine with a dose of 200 mg twice a day for 6 to 8 weeks. Corticosteroids are also used. Intervals between the correct diagnosis and the beginning of the ocular symptoms are commonly delayed. Ophthalmologist should be aware of the ocular manifestation of this autoimmune disease.

1 January 2013 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
LALoredana Arrico
Loredana Arrico
RMRomualdo Malagola
Romualdo Malagola
RGRossella Giannotti
Rossella Giannotti
LPLuigi Pattavina
Luigi Pattavina
Peer reviewed article authored by (Malagola R, Arrico L, Giannotti R, Pattavina L). Read article or submit your manuscript for publishing.

20 November 2014 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
LALoredana Arrico
Loredana Arrico
AAAlessandro Abbouda
Alessandro Abbouda
SBSimona Bianchi
Simona Bianchi
RMRomualdo Malagola
Romualdo Malagola
Discoid lupus erythematosus may lead to significant orbital inflammation syndrome. Ocular manifestations related to discoid lupus erythematosus are uncommon and few cases of eye inflammation are reported.

5 April 2013 in Eye
Verified
Journal Article
Closed access
RMR Malagola
R Malagola
RGR Giannotti
R Giannotti
LPL Pattavina
L Pattavina
LAL Arrico
L Arrico

1 June 2015 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
RMRaffaele Migliorini
Raffaele Migliorini
ACAnna Maria Comberiati
Anna Maria Comberiati
Giovanni GaleotoGiovanni Galeoto
Giovanni Galeoto
MFManuela Fratipietro
Manuela Fratipietro
LALoredana Arrico
Loredana Arrico
Purpose. We evaluated a sample of individuals with retinitis pigmentosa (RP) with the aim of assessing the presence or absence of ocular motility (OM) disorders.Materials and Methods. We included 23 out of the 25 individuals from the sample (9 females and 14 males) with an average visual acuity of 6/10.Results. The cover test about the vertical deviation in near distance showed an r/l in 3.45% and an l/r in 6.9%. The assessment of OM showed that 39.1% of the sample had a severe hyperfunction of the IO of the right eye and a severe hyperfunction (34.5%) of the SO of the left eye; 21.8% had a moderate hypofunction of right SO with a moderate percentage of hypofunction of 17.5% for the SO of the left eye; 30.5%, however, showed a serious hypofunction of the SR of both eyes; 21.7% of the sample showed a hyperfunction in both eyes of the IR.Conclusion. This alteration, however, is not attributable to either a high refractive defect (medium-low myopia: −1 diopter±3 SD) or to a severely impaired binocular vision (visual acuity, motor fusion, and stereopsis are normal or within a range of values commonly accepted). Therefore, the disorders of OM lead to a genetic origin.